← All stocks

Mereo BioPharma Group plc

MREO Net selling

CIK 0001719714 #4717 in the set updated 22 Sep 2026

Bought (120 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$3.08M

$0.00 on a plan · $764.00K straight out of an exercise

Sold at will

$2.32M

22 of 25 sales

Net

−$3.08M

−$2.32M against sales at will

By person

8 insiders · 27 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Hughes-Wilson Alexandra

See Remarks

—

$1.05M (8)

−$1.05M

50,475

0.0063%

$213.05K

—

Scots-Knight Denise

Chief Executive Officer

—

$844.91K (4)

−$844.91K

808,921

0.1013%

$3.41M

+44.3%

PAKIANATHAN DEEPIKA

Director

—

$466.21K (1) scheduled

−$466.21K

0.0000%

$0.00

—

Sermon Charles

General Counsel

—

$294.73K (4)

−$294.73K

219,061

0.0274%

$924.66K

+65.5%

Fox Christine Ann

Chief Financial Officer

—

$269.57K (4)

−$269.57K

89,285

0.0112%

$376.87K

+792.8%

Lewicki John A.

Chief Scientific Officer

—

$153.90K (4)

−$153.90K

78,630

0.0098%

$331.90K

+1,864%

WYZGA MICHAEL S

Director

—

25,050

0.0031%

$105.74K

—

Bender Jeremy

Director

—

12,550

0.0016%

$52.97K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 64

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 1

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 3

Sales at will 22

Transactions with no price 0

Shares from compensation/vesting 1,546,561

History held since 26 Jan 2024